Didanosine once daily: an overview.

Antiviral therapy (2000-03-21)
M Youle

The current focus on simplifying treatment regimens for patients with human immunodeficiency virus (HIV) infection has contributed to the interest in once-daily therapy. The triphosphate of didanosine (2',3'-dideoxyinosine or DDI) has a long intracellular half-life, which supports the use of didanosine in a once-daily dosing schedule. Early clinical studies found that changes in surrogate markers were similar whether didanosine was dosed once or twice daily, while toxic effects occurred less frequently with once-daily dosing. Didanosine once-a-day used in combination with other drugs has also been studied, and results of some of these trials are summarized in this paper.

Product Number
Product Description

Didanosine for system suitability, European Pharmacopoeia (EP) Reference Standard
2′,3′-Dideoxyinosine, ≥98% (HPLC)
Didanosine, European Pharmacopoeia (EP) Reference Standard